Lamotrigine add-on therapy for childhood-onset refractory epilepsy: Comparison of efficacy between 3 months and 6 months after initiation

Kiyoko Watanabe, Katsuhiro Kobayashi, Fumika Endoh, Harumi Yoshinaga, Yoko Ohtsuka

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We investigated the effect of lamotrigine (LTG) add-on therapy in 50 patients with childhood-onset refractory epilepsy (25 males and 25 females): 15 with localization-related epilepsy, 33 with generalized epilepsy, and 2 with undetermined epilepsy. Twenty-four patients had experienced a period of West syndrome during their clinical course. Age at the start of LTG therapy ranged from 2 years 6 months to 41 years 2 months: <16 years in 43 and ≥ 16 years in 7. Seizure frequency was ≥1 per day in 36 patients (72%) and ≥1 per week in 14 (28%). We increased the LTG dosage every two weeks in accordance with usage recommendations. We evaluated efficacy at two points : 3 and 6 months after the start of LTG. At the 6-month point, seizure freedom was achieved in 2 patients (4%), ≥50% seizure reduction in 14 (28%), 25 to 50% seizure reduction in 20 (40%), no effect in 6 (12%), and aggravation in 4 (8%). Only 4 patients (8%) stopped LTG therapy within 6 months due to LTG-related mild skin rash in 2 and suspicion of seizure aggravation in the other 2. In terms of seizure types, seizure freedom or ≥50% seizure reduction was achieved in 29% for epileptic spasms, 32% for tonic seizures, and 29% for partial seizures. A comparison between the 3- and 6-month points revealed that the efficacy level was increased or maintained in 77% of the patients and decreased in 23%. In most cases, the highest level of efficacy appeared within 3 months with doses that were smaller than maintenance doses. Observed CNS-related adverse effects included somnolence in 16 patients, irritability in 14, and sleep disturbance in 11. Positive psychotropic effects in daily activities were seen in 28 patients (56%). These effects appeared regardless of the change in seizure frequency with doses that were smaller than maintenance doses.

Original languageEnglish
Pages (from-to)453-458
Number of pages6
JournalNo To Hattatsu
Volume43
Issue number6
Publication statusPublished - Nov 2011

Fingerprint

Epilepsy
Seizures
Therapeutics
lamotrigine
Infantile Spasms
Generalized Epilepsy
Partial Epilepsy
Spasm
Exanthema
Sleep

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health

Cite this

Lamotrigine add-on therapy for childhood-onset refractory epilepsy : Comparison of efficacy between 3 months and 6 months after initiation. / Watanabe, Kiyoko; Kobayashi, Katsuhiro; Endoh, Fumika; Yoshinaga, Harumi; Ohtsuka, Yoko.

In: No To Hattatsu, Vol. 43, No. 6, 11.2011, p. 453-458.

Research output: Contribution to journalArticle

@article{065704923d52414cbf429bdd5a395e5c,
title = "Lamotrigine add-on therapy for childhood-onset refractory epilepsy: Comparison of efficacy between 3 months and 6 months after initiation",
abstract = "We investigated the effect of lamotrigine (LTG) add-on therapy in 50 patients with childhood-onset refractory epilepsy (25 males and 25 females): 15 with localization-related epilepsy, 33 with generalized epilepsy, and 2 with undetermined epilepsy. Twenty-four patients had experienced a period of West syndrome during their clinical course. Age at the start of LTG therapy ranged from 2 years 6 months to 41 years 2 months: <16 years in 43 and ≥ 16 years in 7. Seizure frequency was ≥1 per day in 36 patients (72{\%}) and ≥1 per week in 14 (28{\%}). We increased the LTG dosage every two weeks in accordance with usage recommendations. We evaluated efficacy at two points : 3 and 6 months after the start of LTG. At the 6-month point, seizure freedom was achieved in 2 patients (4{\%}), ≥50{\%} seizure reduction in 14 (28{\%}), 25 to 50{\%} seizure reduction in 20 (40{\%}), no effect in 6 (12{\%}), and aggravation in 4 (8{\%}). Only 4 patients (8{\%}) stopped LTG therapy within 6 months due to LTG-related mild skin rash in 2 and suspicion of seizure aggravation in the other 2. In terms of seizure types, seizure freedom or ≥50{\%} seizure reduction was achieved in 29{\%} for epileptic spasms, 32{\%} for tonic seizures, and 29{\%} for partial seizures. A comparison between the 3- and 6-month points revealed that the efficacy level was increased or maintained in 77{\%} of the patients and decreased in 23{\%}. In most cases, the highest level of efficacy appeared within 3 months with doses that were smaller than maintenance doses. Observed CNS-related adverse effects included somnolence in 16 patients, irritability in 14, and sleep disturbance in 11. Positive psychotropic effects in daily activities were seen in 28 patients (56{\%}). These effects appeared regardless of the change in seizure frequency with doses that were smaller than maintenance doses.",
author = "Kiyoko Watanabe and Katsuhiro Kobayashi and Fumika Endoh and Harumi Yoshinaga and Yoko Ohtsuka",
year = "2011",
month = "11",
language = "English",
volume = "43",
pages = "453--458",
journal = "No To Hattatsu",
issn = "0029-0831",
publisher = "Japanese Society of Child Neurology",
number = "6",

}

TY - JOUR

T1 - Lamotrigine add-on therapy for childhood-onset refractory epilepsy

T2 - Comparison of efficacy between 3 months and 6 months after initiation

AU - Watanabe, Kiyoko

AU - Kobayashi, Katsuhiro

AU - Endoh, Fumika

AU - Yoshinaga, Harumi

AU - Ohtsuka, Yoko

PY - 2011/11

Y1 - 2011/11

N2 - We investigated the effect of lamotrigine (LTG) add-on therapy in 50 patients with childhood-onset refractory epilepsy (25 males and 25 females): 15 with localization-related epilepsy, 33 with generalized epilepsy, and 2 with undetermined epilepsy. Twenty-four patients had experienced a period of West syndrome during their clinical course. Age at the start of LTG therapy ranged from 2 years 6 months to 41 years 2 months: <16 years in 43 and ≥ 16 years in 7. Seizure frequency was ≥1 per day in 36 patients (72%) and ≥1 per week in 14 (28%). We increased the LTG dosage every two weeks in accordance with usage recommendations. We evaluated efficacy at two points : 3 and 6 months after the start of LTG. At the 6-month point, seizure freedom was achieved in 2 patients (4%), ≥50% seizure reduction in 14 (28%), 25 to 50% seizure reduction in 20 (40%), no effect in 6 (12%), and aggravation in 4 (8%). Only 4 patients (8%) stopped LTG therapy within 6 months due to LTG-related mild skin rash in 2 and suspicion of seizure aggravation in the other 2. In terms of seizure types, seizure freedom or ≥50% seizure reduction was achieved in 29% for epileptic spasms, 32% for tonic seizures, and 29% for partial seizures. A comparison between the 3- and 6-month points revealed that the efficacy level was increased or maintained in 77% of the patients and decreased in 23%. In most cases, the highest level of efficacy appeared within 3 months with doses that were smaller than maintenance doses. Observed CNS-related adverse effects included somnolence in 16 patients, irritability in 14, and sleep disturbance in 11. Positive psychotropic effects in daily activities were seen in 28 patients (56%). These effects appeared regardless of the change in seizure frequency with doses that were smaller than maintenance doses.

AB - We investigated the effect of lamotrigine (LTG) add-on therapy in 50 patients with childhood-onset refractory epilepsy (25 males and 25 females): 15 with localization-related epilepsy, 33 with generalized epilepsy, and 2 with undetermined epilepsy. Twenty-four patients had experienced a period of West syndrome during their clinical course. Age at the start of LTG therapy ranged from 2 years 6 months to 41 years 2 months: <16 years in 43 and ≥ 16 years in 7. Seizure frequency was ≥1 per day in 36 patients (72%) and ≥1 per week in 14 (28%). We increased the LTG dosage every two weeks in accordance with usage recommendations. We evaluated efficacy at two points : 3 and 6 months after the start of LTG. At the 6-month point, seizure freedom was achieved in 2 patients (4%), ≥50% seizure reduction in 14 (28%), 25 to 50% seizure reduction in 20 (40%), no effect in 6 (12%), and aggravation in 4 (8%). Only 4 patients (8%) stopped LTG therapy within 6 months due to LTG-related mild skin rash in 2 and suspicion of seizure aggravation in the other 2. In terms of seizure types, seizure freedom or ≥50% seizure reduction was achieved in 29% for epileptic spasms, 32% for tonic seizures, and 29% for partial seizures. A comparison between the 3- and 6-month points revealed that the efficacy level was increased or maintained in 77% of the patients and decreased in 23%. In most cases, the highest level of efficacy appeared within 3 months with doses that were smaller than maintenance doses. Observed CNS-related adverse effects included somnolence in 16 patients, irritability in 14, and sleep disturbance in 11. Positive psychotropic effects in daily activities were seen in 28 patients (56%). These effects appeared regardless of the change in seizure frequency with doses that were smaller than maintenance doses.

UR - http://www.scopus.com/inward/record.url?scp=82155187114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82155187114&partnerID=8YFLogxK

M3 - Article

C2 - 22180960

AN - SCOPUS:82155187114

VL - 43

SP - 453

EP - 458

JO - No To Hattatsu

JF - No To Hattatsu

SN - 0029-0831

IS - 6

ER -